ERBB2 and breast cancer: At the end of 2019, T-DXd was granted an accelerated FDA approval for advanced, metastatic, or unresectable HER2+ breast cancer based on the DESTINY-Breast01 [82] and the DESTIINY-Breast03 (NCT03529110) [102,103].